statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halozyme to Report Second Quarter 2024 Financial and Operating Results

Halozyme to Report Second Quarter 2024 Financial and Operating Results Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO, July 23, 2024 SAN DIEGO, July 23...

Halozyme Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis Halozyme Announces Roche's OCREVUS SC with ENHANZE...

Decoding 12 Analyst Evaluations For Halozyme Therapeutics

Latest Ratings for HALO
 DateFirmActionFromTo Nov 2021Wells FargoMaintainsOverweight Nov 2021JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkMaintainsOutperform
 View More Analyst...

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy Halozyme Announces argenx Receives FDA Approval...

Halozyme's ENHANZE Product Gets New Patent Grant in EU

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE...

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook PR Newswire SAN DIEGO...

Halozyme Announces Issuance of New European Patent for ENHANZE Drug Delivery Platform

Halozyme Announces Issuance of New European Patent for ENHANZE Drug Delivery Platform Halozyme Announces Issuance of New European Patent for ENHANZE Drug Delivery Platform PR Newswire SAN DIEGO, June...

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire SAN DIEGO, June...

A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE Halozyme Announces Bristol Myers...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Volume	831,949.00
52-Wk High	$56.97
52-Wk Low	$32.83

HALO Halozyme Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals